文献速递中医内科中药与中成药合理使用

荆防败毒散活性组分通过抑制TLR4/Myd88-ERK信号通路减轻克雷伯菌肺炎

Active fractions from Jingfang Baidu Powder alleviate Klebsiella-induced Pneumonia by inhibiting TLR4/Myd88-ERK signaling pathway.
PubMed 文献 · J Ethnopharmacol · 2024-04-16

该研究为探讨荆防败毒散抗肺炎的活性组分及其机制,采用组织病理学观察、RT-qPCR、Western blot和免疫荧光等方法,在克雷伯菌感染肺炎小鼠模型中评价JF30、JF50、JF75三个组分的抗肺炎效果。结果显示三个组分均能不同程度抑制肺组织炎症因子基因表达并呈剂量反应关系,其中JF50抗炎作用最强;JF50可显著降低TLR4、Myd88蛋白表达,抑制p-ERK和p-NF-κB p65,并在25 mg/kg和50 mg/kg剂量下显著抑制Caspase 3、8、9蛋白表达。结论认为JF50通过抑制TLR4/Myd88/NF-κB-ERK信号通路和肺组织细胞凋亡改善克雷伯菌肺炎小鼠肺病理损伤。

要点

  • JF50是荆防败毒散抗克雷伯菌肺炎的主要活性组分,抗炎作用强于JF30和JF75。
  • JF50可抑制TLR4/Myd88/NF-κB-ERK信号通路,并减少肺组织细胞凋亡。
  • 三个组分均能剂量依赖性地抑制肺组织IL-1β、IL-10、CCL3、CCL5、CCL22基因表达。

核心结论

  • JF50通过抑制TLR4/Myd88/NF-κB-ERK信号通路和肺组织细胞凋亡,改善克雷伯菌肺炎小鼠的肺病理损伤。
  • 该研究为进一步探索荆防败毒散治疗细菌性肺炎的活性物质基础提供了参考。

研究设计与样本

  • 研究采用克雷伯菌感染肺炎小鼠模型,评价荆防败毒散中JF30、JF50、JF75三个组分的抗肺炎作用。
  • 检测方法包括组织病理学观察、实时定量PCR、Western blotting和免疫荧光。

主要发现

  • JF30、JF50、JF75三个组分均能不同程度抑制克雷伯菌感染肺组织中IL-1β、IL-10、CCL3、CCL5和CCL22的基因表达,并呈现良好的剂量反应关系。
  • JF50在三个组分中表现出更强的抗炎作用。
  • JF50显著降低克雷伯菌感染肺组织中TLR4和Myd88的蛋白表达,并显著抑制p-ERK和p-NF-κB p65。
  • JF50在25 mg/kg和50 mg/kg剂量下显著抑制克雷伯菌感染肺组织中Caspase 3、Caspase 8和Caspase 9的蛋白表达。

临床怎么用

  • JF50可作为荆防败毒散抗细菌性肺炎的潜在活性组分,为后续制剂改进和临床应用提供参考。
  • 其作用机制涉及抑制TLR4/Myd88/NF-κB-ERK信号通路及减少肺组织细胞凋亡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Jingfang Baidu Powder (JFBDP) is a classic traditional Chinese medicine prescription. Although Jingfang Baidu powder obtained a general consensus on clinical efficacy in treating pneumonia, there were many Chinese herbal drugs in formula, complex components, and large oral dosage, which brings certain obstacles to clinical application. AIM OF THE STUDY: Therefore, screening of the active fraction that exerts anti-pneumonia helps improve the pharmaceutical preparation, improve the treatment compliance of patients, and further contribute to the clinical application, and the screening of the new active ingredients with anti-pneumonia. The histopathological observation, real-time quantitative PCR, western blotting, and immunofluorescence were applied to evaluate the anti-pneumonia efficacy of active fractions from JFBDP. RESULTS: Three fractions from JFBDP inhibit the gene expression of IL-1β, IL-10, CCL3, CCL5, and CCL22 in lung tissue infected by Klebsiella at various degrees, and presented a good dose-response relationship. JF50 showed stronger anti-inflammatory effects among three fractions including JF30, JF50, and JF75. Besides, JF50 significantly reduced the protein expression of TLR4 and Myd88 in lung tissue infected with Klebsiella, and it also significantly inhibited p-ERK and p-NF-κB p65. JF50 significantly inhibits the protein expression of Caspase 3, Caspase 8, and Caspase 9 in lung tissue infected with Klebsiella at the dose of 25 mg/kg and 50 mg/kg. CONCLUSION: JF50 improves lung pathological damage in Klebsiella pneumonia mice by inhibiting the TLR4/Myd88/NF-κB-ERK signaling pathway, and inhibiting apoptosis of lung tissue cells. These findings provide a reference for further exploring the active substance basis of Jingfang Baidu Powder in treating bacterial pneumonia.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Sun C, Xu Y, Xu G, et al. Active fractions from Jingfang Baidu Powder alleviate Klebsiella-induced Pneumonia by inhibiting TLR4/Myd88-ERK signaling pathway. J Ethnopharmacol. 2024. PMID: 38636574. doi:10.1016/j.jep.2024.118067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。